Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Author :

Atsumasa Komori

Clin Mol Hepatol. 2024;30(2):157-159. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0131

View: 1854 Download: 63 Crossref: 2

Atsumasa Komori

Clin Mol Hepatol. 2021;27(1):58-69. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0189

View: 15274 Download: 1,178 Web of Science: 64 Crossref: 77

Atsumasa Komori

Received April 9, 2024 Accepted April 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0242 [Epub ahead of print]

View: 593 Download: 16

Atsumasa Komori

3 Articles

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5405	MAFLD: How is it different from NAFLD?
Viewed By 5215	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5095	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4727	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Author index